Yesterday, Piper Sandler analyst Joseph Catanzaro reiterated a Buy rating on the stock with a price target of $57. In the ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

2023 (Freshman): Appeared in 8 games this season… Recorded two assists on the season… Notched first career collegiate point in a 3-1 loss to Dayton (10/28)... Other assist came against in an Atlantic ...

It’s getting ugly on America’s main streets, with household debt swallowing up consumers’ cash at an alarming rate. According ...

Elutia (Nasdaq:ELUT) announced the first-ever patient implant of its EluPro drug-eluting biologic envelope cleared by the FDA ...

An unsinkable battleship is toasting to nearly a century of feeding everyone from steelworkers to NFL Hall of Famers and even the king of England.

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research ...

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Revolution Medicines (RVMD – Research Report) today and set a price target of $57.00. The company’s shares closed yesterday at $44.54.

Luisa Catanzaro is a director of The Because Movement Foundation and ex-officio member of Museum of Contemporary Art Australia Finance Committee. Ms Catanzaro was chief financial officer of Lynas ...